Sanofi India Limited — Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)

Sanofi India has informed the stock exchanges that it has pending litigation or disputes, as required under a specific regulatory clause. This disclosure is a standard procedural update and does not specify the nature or value of these matters.

For investors, this news is largely procedural. It highlights that the company is managing certain legal challenges, but it does not provide new information about the company's core business performance or financial health. The stock's reaction will likely depend on the market's interpretation of the potential impact of these disputes.

Investors should monitor the company's future filings for any updates on the status or resolution of these legal issues. It is important to wait for more specific details before drawing any conclusions about the company's future prospects.